Results: Eleven patients (IPF, n = 5; PPF, n = 6) were enrolled, and all patients were treated with ramosetron, a 5-hydroxytryptamine type 3 receptor (5-HT3) antagonist. Here, HTR3A is linked to idiopathic pulmonary fibrosis.